What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2020-10-29 compared with 2020-07-30 · 168 added, 158 removed, 205 unchanged (61% of the section changed)

16 unchanged sentences

HealthStream’s customers include healthcare organizations, pharmaceutical and medical device companies, and other participants in the healthcare industry.

At June 30, 2020, we had approximately 3.48 million contracted subscriptions to hStream TM , our Platform-as-a-Service technology.

At September 30, 2020, we had approximately 3.82 million contracted subscriptions to hStream TM , our Platform-as-a-Service technology.

hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.

1 unchanged sentence

Prior to the disposition of the PX business, our Patient Experience Solutions products provided our customers information about patients’ experiences and how to improve them, workforce engagement, physician relations, and community perceptions of their services.

The gain on sale of the PX business recorded in prior periods are reflected in the Company’s Consolidated Financial Statements as discontinued operations for the six months ended June 30, 2019.

Our results for the three months ended June 30, 2020 and 2019 and for the six months ended June 30, 2020 do not include any discontinued operations.

Except where otherwise noted herein, our results for the six months ended June 30, 2020 and 2019 are presented on a continuing operations basis.

The gain on sale of the PX business recorded in prior periods are reflected in the Company’s Consolidated Financial Statements as discontinued operations for the three and nine months ended September 30, 2019.

Our results for the three and nine months ended September 30, 2020 do not include any discontinued operations.

Except where otherwise noted herein, our results are presented on a continuing operations basis.

This sale of the PX business resulted in the Company’s divestiture of the patient experience solutions business segment.

Significant financial metrics for the second quarter of 2020 are set forth in the bullets below.

Revenues of $60.6 million in the second quarter of 2020, down 5% from $63.8 million in the second quarter of 2019

Operating income of $4.3 million in the second quarter of 2020 compared to $2.3 million in the second quarter of 2019

Net income of $3.4 million in the second quarter of 2020, up 43% from $2.4 million in the second quarter of 2019

Earnings per share (EPS) of $0.11 per share (diluted) in the second quarter of 2020 compared to EPS of $0.07 per share (diluted) in the second quarter of 2019

Adjusted EBITDA 1 of $12.0 million in the second quarter of 2020, up 2% from $11.8 million in the second quarter of 2019

Adjusted EBITDA is a non-GAAP financial measure.

A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this report.

During the second quarter of 2019 , Robert A.

contributed 78,520 of his personally owned shares of common stock (with a value of $2.0 million) to the Company for the benefit of HealthStream employees, without any consideration paid to Mr.

In connection therewith, the Company approved the grant of the same number of shares under its 2016 Omnibus Incentive Plan to approximately 820 of its employees.

These shares were issued in July 2019.

Frist also contributed an additional 7,852 of his personally owned shares to cover the Company’s costs associated with such grants, such as administrative expenses and employer payroll taxes.

Together, these grants resulted in the Company recognizing approximately $2.0 million stock based compensation expense and $0.2 million payroll tax expense in the second quarter of 2019.

The only shareholder who was diluted from these transactions was Mr.

See Note 5 to the Condensed Consolidated Financial Statements, included within this report, for additional information.

Significant financial metrics for the third quarter of 2020 are set forth in the bullets below.

Revenues of $60.9 million in the third quarter of 2020, down 3% from $62.5 million in the third quarter of 2019

Operating income of $3.1 million in the third quarter of 2020, down 16% from $3.7 million in the third quarter of 2019

Income from continuing operations of $2.6 million in the third quarter of 2020, down 24% from $3.5 million in the third quarter of 2019

Earnings per share (EPS) from continuing operations of $0.08 per share (diluted) in the third quarter of 2020 down from $0.11 per share (diluted) in the third quarter of 2019

Adjusted EBITDA 1 from continuing operations of $11.1 million in the third quarter of 2020, down 3% from $11.5 million in the third quarter of 2019

Adjusted EBITDA from continuing operations is a non-GAAP financial measure.

A reconciliation of adjusted EBITDA from continuing operations to income from continuing operations and disclosure regarding why we believe adjusted EBITDA from continuing operations provides useful information to investors is included later in this report.

On March 9, 2020, the Company acquired all of the outstanding stock of HcT2 Co.

dba NurseGrid (“NurseGrid”), a Portland, Oregon-based healthcare technology company offering NurseGrid Mobile and its corollary application for nurse managers, NurseGrid Enterprise, for net cash consideration of approximately $21.5 million, after giving effect to the post-closing working capital adjustment.

The financial results of NurseGrid have been included in the Workforce Solutions segment from March 9, 2020.

Impact of and Response to COVID-19 Pandemic

3 unchanged sentences

Additionally, some governmental authorities have reinstated previously relaxed restrictions due to a recent rise in diagnosed cases of COVID-19 in many regions of the United States.

This pandemic has also led to significant disruption and volatility in financial and capital markets.

Our business is focused on providing workforce and provider solutions to healthcare organizations, such that the pandemic’s adverse impact on healthcare organizations has resulted in an adverse impact on our Company.

Although we believe that COVID-19 did not have a significant negative impact on our revenues or net income during the first six months of 2020, certain developments related to COVID-19 have negatively impacted, and are expected to continue to negatively impact, our business this year and potentially longer, as described below.

Our operating income for the second quarter of 2020 benefited from a temporary reduction of operating expenses related to COVID-19 conditions, but the operating expense reduction itself—despite its positive impact on operating income in the quarter—is indicative of the negative impact the pandemic is having on sales.

We have experienced, and expect to continue to experience, delayed and reduced sales volumes due to the pandemic.

This pandemic has also led to disruption and volatility in financial and capital markets.

Our business is focused on providing workforce and provider solutions to healthcare organizations, and as such the pandemic’s adverse impact on healthcare organizations has resulted in an adverse impact on our Company.

Although we believe that COVID-19 did not have a significant negative impact on our revenues or net income during the first nine months of 2020, certain developments related to COVID-19 have negatively impacted, and are expected to continue to negatively impact, our business this year and potentially longer, as described below.

Our operating income for the nine months ended September 30, 2020 benefited from a temporary reduction of operating expenses related to COVID-19 conditions, but the operating expense reduction itself—despite its positive impact on operating income—is indicative of the negative impact the pandemic is having on new bookings and renewals.

We have experienced, and expect to continue to experience, delayed and reduced bookings and renewals due to the pandemic.

Given that we sell multiple year subscriptions to our solutions, the revenue impact of lost or delayed sales in a given period generally does not manifest until future periods, just as the revenue we recognize in a given period is generally the result of sales from a prior period.

Since mid-March, our sales team has been unable to travel and conduct onsite sales meetings with existing or prospective customers, and we have also cancelled tradeshows.

While operating income benefitted from a $1.1 million reduction in operating expense related to the discontinuance of travel and a $0.2 million reduction in operating expenses related to the cancellation of tradeshows during the second quarter of 2020 compared to the same period last year, the practical implication was the loss of sales opportunities that would have likely converted to revenue in future periods.

As a result, operating income benefitted from a $2.2 million reduction in operating expense related to the discontinuance of travel and a $0.2 million reduction in operating expenses related to the cancellation of tradeshows during the first nine months of 2020 compared to the same period last year.

The extent, timing, and duration of the impacts of the COVID-19 pandemic on our business remain uncertain, and will depend upon, among other things, the length and severity of the pandemic, particularly with respect to the pandemic’s ongoing impact on healthcare organizations.

4 unchanged sentences

In March, we made available to all caregivers, free of charge, a curated library of proprietary content and to our customers, a bundle of cross-training courses to further their staff’s preparation to deliver safe and effective care to COVID-19 patients.

This has resulted in approximately 2.2 million course completions related to COVID-19 through June 30, 2020, including courses self-authored by customers and proprietary courses, over our technology platform.

This has resulted in approximately 3.0 million course completions related to COVID-19 through September 30, 2020, including courses self-authored by customers and proprietary courses, over our technology platform.

Additionally, as previously announced, HealthStream, in partnership with the State of Tennessee Office of the Governor, is providing its COVID-19 Rapid Response Program, which includes training bundles and its workforce platform, along with other workforce resources to support the state’s efforts to rapidly train new, returning, and current caregivers who are volunteering to work in Alternate Healthcare Facilities being set-up across the state.

3 unchanged sentences

Many healthcare organizations have been, and will likely continue to be, substantially adversely impacted by the COVID-19 pandemic.

The period of time over which this adverse impact continues, the extent to which certain healthcare organizations continue to receive governmental funds as the result of federal stimulus and relief measures, and whether conditions related to the pandemic continue to deteriorate are important factors that may impact our business.

The period of time over which this adverse impact continues , the extent to which certain healthcare organizations continue to receive and/or are eligible to utilize governmental funds as the result of federal stimulus and relief measures, and whether conditions related to the pandemic continue to deteriorate are important factors that may impact our business.

The pandemic has resulted in a significant reduction of revenue generating services for many healthcare organizations, such as elective surgeries and other elective procedures, while, in some cases, their cost of providing emergency care as the result of treating COVID-19 patients has increased.

Adverse COVID-19 impacts such as these have resulted, and will likely continue to result, in healthcare organizations curtailing operations, furloughing employees, eliminating positions, reducing operating and capital expenditures, and even, in some instances, declaring bankruptcy.

Adverse COVID-19 impacts such as these have result ed , and may continue to result, in significant adverse impacts to many healthcare organizations .

In light of adverse developments with respect to healthcare organizations as noted above, we are continuing to monitor the ability or willingness of our customers to:

3 unchanged sentences

We monitor our cash position and credit exposure by evaluating, among other things, weekly cash receipts, days sales outstanding (“DSO”), customer requests to modify payment or contract terms, and bankruptcy notices.

We experienced a decrease in cash receipts from customers in the second quarter of 2020 compared to the same period of the previous year and an increase in DSO from the first quarter of 2020 to the second quarter.

Our DSO was 47 days for the second quarter of 2020, which was the same as the prior year, but rose from 44 days in the first quarter of 2020.

We experienced a decrease in cash receipts from customers in the first nine months of 2020 compared to the same period of the previous year and an increase in DSO from 40 days in the third quarter of 2019 to 43 days for the third quarter of 2020.

While our cash balances increased by $5.2 million during the quarter, our cash flows from operations were $30.8 million this year compared to $52.5 million in the prior year, which was due primarily to the decline in legacy resuscitation sales and the impact of COVID-19.

8 unchanged sentences

In addition, many of our customers are not currently allowing vendors, including representatives of the Company, on their premises, which has been reducing the ability of our sales team to make sales they otherwise would likely make but for the impact of COVID-19.

As discussed above, the inability to travel and conduct tradeshows has had, and is likely to continue to have, a negative impact on our sales volumes.

In addition, our customer’s uncertainties due to COVID-19, combined with the inability to travel and conduct tradeshows, has had, and is likely to continue to have, a negative impact on our sales volumes.

We continue to pursue new sales strategies, including those that do not require in-person meetings, tradeshows, or travel.

Our business also relies on a network of partners whose solutions we resell or whose solutions are sold and delivered over our platform.

1 unchanged sentence

To the extent COVID-19 results in business disruption or adverse impacts to our partners, such disruptions and adverse impacts could adversely impact our business.

Given the uncertainty surrounding the adverse impact that COVID-19 may have on our business, we have taken certain expense management measures.

These include:

Indefinitely postponing, and potentially foregoing, increases to base salaries in 2020, including executive base salaries.

Given the uncertainty surrounding the adverse impact that COVID-19 may have on our business, we have taken certain expense management measures, which have included:

Foregoing increases to base salaries in 2020, including executive base salaries.

Normally, base salary increases become effective May 1 st .

5 unchanged sentences

Evaluating iterative reductions to our capital expenditures to be deployed on an as-needed basis.

These expense management measures contributed to the decrease in our operating expenses, which declined by approximately $1.7 million during the three months ended June 30, 2020 compared to the prior year period.

T hese expense management measures contributed to the decrease in our operating expenses , which compared to the prior year period declined by approximately $1.7 million and $3.4 million during the three and nine months ended September 30, 2020 , respectively .

Additionally, we are continuing to monitor developments regarding the COVID-19 pandemic and may undertake further expense management initiatives if we deem necessary.

The Company’s financial performance during the pandemic has remained solid, partly due to the above expense control measures.

While we believe these expense control measures are prudent in light of current conditions, we also intend to strike a balance to ensure that our operations are financially stable for the future and that we continue to achieve our growth objectives.

Our employees are vitally important to our success, and they have made numerous contributions during these unprecedented times.

Although we have forgone salary increases for 2020 and previously limited the 401k match to one percent as noted above, during the third quarter we elected to provide our employees, excluding executive officers, with a supplemental payroll payment and an increase of the 401k match from one percent to two percent for all employees.

The supplemental payroll payment approximates the dollar amount of salary increases that were foregone in 2020 as noted above.

The impact of these two items reduced operating income by approximately $1.9 million during the third quarter.

Key Business Metrics

3 unchanged sentences

Operating income represents the amount of profit realized from our operations and is calculated as the difference between revenues, net and operating costs and expenses.

Operating income was $4.3 million and $11.5 million for the three and six months ended June 30, 2020 compared to $2.3 million and $7.6 million for the three and six months ended June 30, 2019.

Operating income was $3.1 million and $14.7 million for the three and nine months ended September 30, 2020 compared to $3.7 million and $11.4 million for the three and nine months ended September 30, 2019.

Management utilizes operating income in connection with managing our business as a key indicator of profitability.

3 unchanged sentences

Adjusted EBITDA, calculated as set forth below under “Reconciliation of Non-GAAP Financial Measures,” is utilized by our management in connection with managing our business and provides useful information to investors because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items, as more specifically set forth below.

Management further believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the gain on sale in connection with the sale of the PX business in February 2018 included in our results of operations during the six months ended June 30, 2019, and thus reflects the Company’s ongoing business operations and assists in comparing the Company’s results of operations between periods.

Management further believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the gain on sale in connection with the sale of the PX business in February 2018 included in our results of operations during the three and nine months ended September 30, 2019, and thus reflects the Company’s ongoing business operations and assists in comparing the Company’s results of operations between periods.

We believe that adjusted EBITDA and adjusted EBITDA from continuing operations are useful to many investors to assess the Company’s ongoing results from current operations.

Adjusted EBITDA was $12.0 million for the three months ended June 30, 2020 compared to $11.8 million for the three months ended June 30, 2019.

Adjusted EBITDA from continuing operations was $11.1 million and $34.9 million for the three and nine months ended September 30, 2020 compared to $11.5 million and $35.7 million for the three and nine months ended September 30, 2019.

hStream Subscriptions .

1 unchanged sentence

Our management utilizes hStream subscriptions in connection with managing our business and believes this metric provides useful information to investors as a measure of our progress in growing the value of our customer base.

At June 30, 2020, we had approximately 3.48 million contracted subscriptions to hStream compared to 2.34 million as of June 30, 2019.

At September 30, 2020, we had approximately 3.82 million contracted subscriptions to hStream compared to 2.78 million as of September 30, 2019.

Critical Accounting Policies and Estimates

14 unchanged sentences

There have been no material changes in our critical accounting policies and estimates from those reported in our 2019 Form 10-K.

Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019

Three Months Ended September 30, 2020 Compared to Three Months Ended September 30, 2019

Revenues, net.

Revenues decreased $3.2 million, or 5%, to $60.6 million for the three months ended June 30, 2020 from $63.8 million for the three months ended June 30, 2019.

Revenues decreased $1.6 million, or 3%, to $60.9 million for the three months ended September 30, 2020 from $62.5 million for the three months ended September 30, 2019.

A comparison of revenues by business segment is as follows (in thousands):

Three Months Ended June 30,

Three Months Ended September 30,

Revenues by Business Segment:

5 unchanged sentences

Provider Solutions

Revenues for Workforce Solutions decreased $3.5 million, or 7%, to $48.9 million for the three months ended June 30, 2020 from $52.4 million for the three months ended June 30, 2019.

Revenues from legacy resuscitation products decreased by $4.8 million, from $10.7 million in the second quarter of 2020 compared to $15.5 million in the second quarter of 2019.

Other workforce revenues increased by $1.3 million, representing an increase in platform and content subscriptions of $1.8 million, or 5%, partially offset by a decline in professional services revenues of $0.5 million, or 34%, due to fewer projects than the prior year.

Revenues for Provider Solutions increased $0.3 million, or 3%, to $11.7 million for the three months ended June 30, 2020 from $11.4 million for the three months ended June 30, 2019.

Revenues for Workforce Solutions decreased $1.8 million, or 4%, to $49.2 million for the three months ended September 30, 2020 from $51.0 million for the three months ended September 30, 2019.

Revenues from legacy resuscitation products decreased by $3.7 million and were $9.7 million in the third quarter of 2020 compared to $13.4 million in the third quarter of 2019.

Other workforce revenues increased by $1.9 million, or 5%, and included growth in platform and content subscriptions of $2.6 million, or 7%, partially offset by a decline in professional services revenues of $0.7 million, or 43%, due to fewer projects than the prior year.

Revenues for Provider Solutions increased $0.3 million, or 2%, to $11.7 million for the three months ended September 30, 2020 from $11.4 million for the three months ended September 30, 2019.

Revenue growth of $0.3 million was primarily attributable to $0.4 million in revenues from the CredentialMyDoc acquisition, which was completed in December 2019, partially offset by a decline in professional services $0.1 million.

Cost of Revenues (excluding depreciation and amortization).

Cost of revenues decreased $3.9 million, or 14%, to $22.9 million for the three months ended June 30, 2020 from $26.8 million for the three months ended June 30, 2019.

Cost of revenues as a percentage of revenues was 38% and 42% for the three months ended June 30, 2020 and 2019, respectively.

Cost of revenues for Workforce Solutions decreased $3.8 million to $19.1 million and approximated 39% and 44% of revenues for Workforce Solutions for the three months ended June 30, 2020 and 2019, respectively.

The decrease is primarily associated with decreased royalties paid by us resulting from a decline in revenues and lower stock based compensation driven by the impact of the stock awards granted to employees facilitated by our Chief Executive Officer during the three months ended June 30, 2019 as described above.

Cost of revenues for Provider Solutions decreased $76,000 to $3.8 million and approximated 33% and 35% of Provider Solutions revenues for the three months ended June 30, 2020 and 2019, respectively.

The decrease is primarily associated with lower stock based compensation resulting from the impact of the stock awards granted during the three months ended June 30, 2019 as noted above.

Cost of revenues decreased $2.0 million, or 8%, to $23.3 million for the three months ended September 30, 2020 from $25.3 million for the three months ended September 30, 2019.

Cost of revenues as a percentage of revenues was 38% and 41% for the three months ended September 30, 2020 and 2019, respectively.

Cost of revenues for Workforce Solutions decreased $2.2 million to $19.3 million and approximated 39% and 42% of revenues for Workforce Solutions for the three months ended September 30, 2020 and 2019, respectively.

The decrease is primarily associated with decreased royalties paid by us resulting from a decline in revenues and lower travel expense.

Cost of revenues for Provider Solutions increased $0.2 million to $4.0 million and approximated 34% and 33% of Provider Solutions revenues for the three months ended September 30, 2020 and 2019, respectively.

The increase is primarily associated with the supplemental payroll payment recorded during the three months ended September 30, 2020 as noted above.

Product Development.

Product development expenses increased $0.2 million, or 2%, to $7.8 million for the three months ended June 30, 2020 from $7.6 million for the three months ended June 30, 2019.

Product development expenses as a percentage of revenues were 13% and 12% for the three months ended June 30, 2020 and 2019, respectively.

Product development expenses for Workforce Solutions decreased $0.2 million to $6.2 million and approximated 13% and 12% of revenues for Workforce Solutions for the three months ended June 30, 2020 and 2019, respectively.

The decrease in amount is primarily due to lower stock based compensation as the result of the impact of the stock awards granted during the three months ended June 30, 2019 as noted above.

Product development expenses for Provider Solutions increased $0.4 million to $1.6 million and approximated 14% and 11% of revenues for Provider Solutions for the three months ended June 30, 2020 and 2019, respectively.

The increase is primarily due to an increase in contract labor and personnel costs.

Product development expenses increased $1.0 million, or 14%, to $8.2 million for the three months ended September 30, 2020 from $7.2 million for the three months ended September 30, 2019.

Product development expenses as a percentage of revenues were 13% and 12% for the three months ended September 30, 2020 and 2019, respectively.

Product development expenses for Workforce Solutions increased $0.6 million to $6.5 million and approximated 13% and 11% of revenues for Workforce Solutions for the three months ended September 30, 2020 and 2019 , respectively.

The increase in amount is primarily due to additions to personnel resulting from the NurseGrid acquisition and the supplemental payroll payment to employees as noted above .

Product development expenses for Provider Solutions increased $0.4 million to $1.7 million and approximated 15% and 12% of revenues for Provider Solutions for the three months ended September 30, 2020 and 2019 , respectively.

The increase is primarily due to an increase in contract labor and additions to personnel resulting from the CredentialMyDoc acquisition .

Sales and Marketing.

Sales and marketing expenses, including personnel costs, decreased $1.6 million, or 16%, to $8.2 million for the three months ended June 30, 2020 from $9.8 million for the three months ended June 30, 2019.

Sales and marketing expenses were 14% and 15% of revenues for the three months ended June 30, 2020 and 2019, respectively.

Sales and marketing expenses for Workforce Solutions decreased $1.6 million to $6.4 million and approximated 13% and 15% of revenues for Workforce Solutions for the three months ended June 30, 2020 and 2019, respectively.

The decrease is primarily due lower sales commissions, consistent with the decreases in revenues, decreases in travel and entertainment expenses as well as tradeshow expenses as a result of COVID-19 conditions as set forth above, as well as a lower stock based compensation resulting from the impact of the stock awards granted during the three months ended June 30, 2019 as noted above.

Sales and marketing expenses for Provider Solutions decreased $11,000 to $1.5 million and approximated 13% and 14% of revenues for Provider

Solutions for the three months ended June 30, 2020 and 2019 , respectively .

The unallocated portion of sales and marketing expenses increased $45,000 to $0.3 million compared to the prior year period.

Sales and marketing expenses, including personnel costs, decreased $0.1 million, or 2%, to $8.9 million for the three months ended September 30, 2020 from $9.0 million for the three months ended September 30, 2019.

Sales and marketing expenses were 15% and 14% of revenues for the three months ended September 30, 2020 and 2019, respectively.

Sales and marketing expenses for Workforce Solutions decreased $0.2 million to $7.0 million and approximated 14% of revenues for Workforce Solutions for both the three months ended September 30, 2020 and 2019.

The decrease is primarily due to lower travel and entertainment expenses as a result of COVID-19 and lower sales commissions consistent with the decreases in revenues.

Sales and marketing expenses for Provider Solutions increased $0.1 million to $1.6 million and approximated 14% and 13% of revenues for Provider Solutions for the three months ended September 30, 2020 and 2019, respectively.

The increase is primarily due to additions to personnel resulting from the CredentialMyDoc acquisition and the supplemental payroll payment to employees as noted above.

The unallocated portion of sales and marketing expenses decreased $26,000 to $0.3 million compared to the prior year period.

Other General and Administrative Expenses.

Other general and administrative expenses decreased $0.2 million, or 2%, to $10.1 million for the three months ended June 30, 2020 from $10.3 million for the three months ended June 30, 2019.

Other general and administrative expenses as a percentage of revenues were 17% and 16% of revenues for the three months ended June 30, 2020 and 2019, respectively.

Other general and administrative expenses for Workforce Solutions increased $0.3 million to $3.9 million and approximated 8% and 7% of Workforce Solutions revenues for the three months ended June 30, 2020 and 2019, respectively.

The increase is primarily due to increases in infrastructure expenses and the acquisition of NurseGrid in March 2020.

Other general and administrative expenses for Provider Solutions increased $18,000 to $0.8 million and approximated 7% of Provider Solutions revenues for both the three months ended June 30, 2020 and 2019.

The unallocated corporate portion of other general and administrative expenses decreased $0.5 million to $5.4 million compared to the prior year period primarily due to decreases to contract labor and stock based compensation resulting from the impact of the stock awards granted during the three months ended June 30, 2019 as noted above.

Other general and administrative expenses approximated $10.0 million for both the three months ended September 30, 2020 and 2019.

Other general and administrative expenses as a percentage of revenues were 16% of revenues for both the three months ended September 30, 2020 and 2019.

Other general and administrative expenses for Workforce Solutions increased $71,000 to $3.4 million and approximated 7% of Workforce Solutions revenues for both the three months ended September 30, 2020 and 2019.

Other general and administrative expenses for Provider Solutions decreased $95,000 to $0.9 million and approximated 7% and 8% of Provider Solutions revenues for the three months ended September 30, 2020 and 2019, respectively.

The unallocated corporate portion of other general and administrative expenses approximated $5.7 million for both the current and prior year period.

Higher expenses associated with due diligence costs, including costs related to our acquisition of ShiftWizard which was completed in October 2020, incurred in the quarter were mostly offset by reductions in other expense categories.

Depreciation and Amortization.

Depreciation and amortization increased $0.3 million, or 3%, to $7.2 million for the three months ended June 30, 2020 from $6.9 million for the three months ended June 20, 2019.

Depreciation and amortization increased $0.3 million, or 4%, to $7.4 million for the three months ended September 30, 2020 from $7.1 million for the three months ended September 30, 2019.

The increase resulted from an increase in amortization of capitalized software and intangible assets.

Other Income, Net .

Other income, net was $0.2 million for the three months ended June 30, 2020 compared to $0.9 million for the three months ended June 30, 2019.

The decrease is a result of lower interest income from cash and investments in marketable securities due to reductions in bond yields and bank interest rates.

Other income, net was $0.1 million for the three months ended September 30, 2020 compared to $0.9 million for the three months ended September 30, 2019.

The decrease is a result of lower interest income from cash and investments in marketable securities due to reductions in bond yields and bank deposit interest rates.

Income Tax Provision.

The Company recorded a provision for income taxes of $1.1 million for the three months ended June 30, 2020 compared to $0.7 million for the three months ended June 30, 2019.

The Company’s effective tax rate was 24% and 23% for the three months ended June 30, 2020 and 2019, respectively.

Net income was $3.4 million in the second quarter of 2020, up 43% from $2.4 million in the second quarter of 2019, which increase was driven by the $1.7 million charge, net of tax, associated with the stock grant to employees that occurred in June 2019.

Earnings per diluted share were $0.11 and $0.07 per share for the three months ended June 30, 2020 and 2019, respectively.

Adjusted EBITDA (a non-GAAP financial measure which we define as net income before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, and the de-recognition of non-cash royalty expense resulting from our resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to costs of revenues in the first quarter of 2020) increased 2% to $12.0 million for the three months ended June 30, 2020 compared to $11.8 million for the three months ended June 30, 2019.

See “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of Adjusted EBITDA to the most directly comparable measures under US GAAP.

Six Months Ended June 30, 2020 Compared to Six Months Ended June 30, 2019

The Company recorded a provision for income taxes of $0.6 million for the three months ended September 30, 2020 compared to $1.1 million for the three months ended September 30, 2019.

The Company’s effective tax rate was 19% and 25% for the three months ended September 30, 2020 and 2019, respectively.

The decrease in the effective tax rate is primarily due to the recognition of tax benefits resulting from higher research and development tax credits than previously estimated.

Income from Continuing Operations.

Income from continuing operations was $2.6 million in the third quarter of 2020, down 24% from $3.5 million in the third quarter of 2019, which decrease was driven by the $1.5 million expense, net of tax, associated with the supplemental payroll payment to employees and the additional 401k match as noted above.

Earnings per diluted share from continuing operations were $0.08 and $0.11 for the three months ended September 30, 2020 and 2019, respectively.

Income from Discontinued Operations.

Income from discontinued operations was zero for the three months ended September 30, 2020 compared to $0.3 million for the three months ended September 30, 2019.

Net income was $2.6 million in the third quarter of 2020 compared to $3.7 million in the third quarter of 2019.

Earnings per diluted share were $0.08 and $0.11 for the three months ended September 30, 2020 and 2019, respectively.

Adjusted EBITDA (a non-GAAP financial measure which we define as net income before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, and the de-recognition of non-cash royalty expense resulting from our resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to costs of revenues in the first quarter of 2020) from continuing operations decreased 3% to $11.1 million for the three months ended September 30, 2020 compared to $11.5 million for the three months ended September 30, 2019.

Adjusted EBITDA decreased to $11.1 million for the three months ended September 30, 2020 compared to $11.8 million for the three months ended September 30, 2019.

S ee “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of Adjusted EBITDA from continuing operations and Adjusted EBITDA to the most directly comparable measures under US GAAP.

Nine Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019

Revenues, net.

Revenues decreased $6.8 million, or 5%, to $122.1 million for the six months ended June 30, 2020 from $129.0 million for the six months ended June 30, 2019.

Revenues decreased $8.4 million, or 4%, to $183.0 million for the nine months ended September 30, 2020 from $191.4 million for the nine months ended September 30, 2019.

A comparison of revenues by business segment is as follows (in thousands):

Six Months Ended

Nine Months Ended

September 30,

Revenues by Business Segment:

5 unchanged sentences

Provider Solutions

Revenues for Workforce Solutions decreased $8.0 million, or 8%, over the first six months of 2019.

Revenue from our legacy resuscitation products declined by $10.9 million, which were $21.9 million in the first six months of 2020 compared to $32.8 million in the first six months of 2019.

Other workforce revenues increased by $2.9 million, representing an increase in platform

and content subscriptions of $3.5 million, or 5%, partially offset by a decline in professional services revenues of $0.

6 million, or 23%.

Revenues for Provider Solutions increased $1.2 million, or 5%, over the first six months of 2019.

Revenues for Workforce Solutions decreased $9.8 million, or 6%, over the first nine months of 2019.

Revenue from our legacy resuscitation products declined by $14.7 million and were $31.6 million in the first nine months of 2020 down from $46.3 million in the first nine months of 2019.

Other workforce revenues increased by $4.9 million, representing an increase in platform and content subscriptions of $6.2 million, or 6%, partially offset by a decline in professional services revenues of $1.3 million, or 30%.

Revenues for Provider Solutions increased $1.4 million, or 4%, over the first nine months of 2019.

Revenue growth was primarily attributable to the CredentialMyDoc acquisition, which was completed in December 2019, contributing $1.2 million in revenues, along with new VerityStream platform subscriptions and professional services for implementation of new customers.

Cost of Revenues (excluding depreciation and amortization).

Cost of revenues decreased $10.4 million, or 19%, to $43.3 million for the six months ended June 30, 2020 from $53.7 million for the six months ended June 30, 2019.

Cost of revenues as a percentage of revenues was 35% and 42% for the six months ended June 30, 2020 and 2019, respectively.

Cost of revenues for Workforce Solutions decreased $10.6 million to $35.5 million and approximated 36% and 43% of revenues for Workforce Solutions for the six months ended June 30, 2020 and 2019, respectively.

The decrease is primarily associated with the favorable $3.4 million contractual adjustment that resulted in a decrease to royalty expense upon the resolution of a mutual disagreement relating to various elements of a past partnership recorded in the first quarter of 2020.

In addition, cost of revenues for Workforce Solutions benefited from lower royalty expense associated with the decline in the legacy resuscitation revenues and lower stock based compensation resulting from the impact of the stock awards granted to employees facilitated by our Chief Executive Officer during the six months ended June 30, 2019 as noted above.

Cost of revenues for Provider Solutions increased $0.2 million to $7.8 million and approximated 33% and 34% of Provider Solutions revenues for the six months ended June 30, 2020 and 2019, respectively.

The increase in amount is primarily due to increased personnel over the prior year period.

Cost of revenues decreased $12.4 million, or 16%, to $66.6 million for the nine months ended September 30, 2020 from $79.0 million for the nine months ended September 30, 2019.

Cost of revenues as a percentage of revenues was 36% and 41% for the nine months ended September 30, 2020 and 2019, respectively.

Cost of revenues for Workforce Solutions decreased $12.8 million to $54.8 million and approximated 37% and 43% of revenues for Workforce Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The decrease is primarily associated with the lower royalty expense associated with the decline in the legacy resuscitation revenues along with the favorable $3.4 million contractual adjustment that resulted in a decrease to royalty expense upon the resolution of a mutual disagreement relating to various elements of a past partnership recorded in the first quarter of 2020.

Cost of revenues for Provider Solutions increased $0.4 million to $11.8 million and approximated 34% of Provider Solutions revenues for both the nine months ended September 30, 2020 and 2019.

The increase in amount is primarily due to increased personnel over the prior year period, including the addition of personnel from the CredentialMyDoc acquisition, and the supplemental payroll payment to employees as noted above.

Product Development.

Product development expenses increased $0.7 million, or 5%, to $15.3 million for the six months ended June 30, 2020 from $14.6 million for the six months ended June 30, 2019.

Product development expenses as a percentage of revenues were 13% and 11% of revenues for the six months ended June 30, 2020 and 2019, respectively.

Product development expenses for Workforce Solutions decreased $0.1 million to $12.1 million and approximated 12% and 11% of revenues for Workforce Solutions for the six months ended June 30, 2020 and 2019, respectively.

The decrease in amount is primarily due to lower stock based compensation as the result of the impact of the stock awards granted during the three months ended June 30, 2019 as noted above.

Product development expenses for Provider Solutions increased $0.8 million to $3.2 million and approximated 14% and 11% of revenues for HealthStream Solutions for the six months ended June 30, 2020 and 2019, respectively.

The increase is primarily due to increased personnel and contract labor over the prior year period.

Product development expenses increased $1.7 million, or 8%, to $23.5 million for the nine months ended September 30, 2020 from $21.8 million for the nine months ended September 30, 2019.

Product development expenses as a percentage of revenues were 13% and 11% for the nine months ended September 30, 2020 and 2019, respectively.

Product development expenses for Workforce Solutions increased $0.5 million to $18.5 million and approximated 13% and 11% of revenues for Workforce Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The increase is primarily due to increased personnel as a result of the NurseGrid acquisition in March 2020.

Product development expenses for Provider Solutions increased $1.2 million to $5.0 million and approximated 14% and 11% of revenues for HealthStream Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The increase is primarily due to increased contract labor and increased personnel over the prior year period as a result of the CredentialMyDoc acquisition.

Sales and Marketing.

Sales and marketing expenses, including personnel costs, decreased $1.9 million, or 10%, to $17.4 million for the six months ended June 30, 2020 from $19.3 million for the six months ended June 30, 2019.

Sales and marketing expenses were 14% and 15% of revenues for the six months ended June 30, 2020 and 2019, respectively.

Sales and marketing expenses for Workforce Solutions decreased $2.1 million to $13.7 million and approximated 14% and 15% of revenues for Workforce Solutions for the six months ended June 30, 2020 and 2019, respectively.

The decrease is primarily due to lower sales commissions, consistent with the decreases in revenues, decreases in travel and entertainment expenses as well as tradeshow expenses as a result of COVID-19 conditions as set forth above, and declines in general marketing expenses.

Sales and marketing expenses for Provider Solutions increased $0.1 million to $3.1 million and approximated 13% of revenues for Provider Solutions for both the six months ended June 30, 2020 and 2019.

Sales and marketing expenses, including personnel costs, decreased $2.1 million, or 7%, to $26.3 million for the nine months ended September 30, 2020 from $28.3 million for the nine months ended September 30, 2019.

Sales and marketing expenses were 14% and 15% of revenues for the nine months ended September 30, 2020 and 2019, respectively.

Sales and marketing expenses for Workforce Solutions decreased $2.4 million to $20.8 million and approximated 14% and 15% of revenues for Workforce Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The decrease is primarily due to lower sales commissions, consistent with the decreases in revenues, decreases in travel and entertainment

expenses as well as tradeshow expenses as a result of COVID-1 9 conditions as set forth above, and dec lines in general marketing expenses.

Sales and marketing expenses for Provider Solutions increased $0.3 million to $4.7 million and approximated 13% of revenues for Provider Solutions for both the nine months ended September 30, 2020 and 2019 .

The increase in amount is primarily due to higher sales commissions, consistent with the increases in revenues .

The unallocated portion of sales and marketing expenses increased $29,000 to $0.6 million compared to the prior year period.

The unallocated portion of sales and marketing expenses approximated $0.8 million for both the current and prior year period.

Other General and Administrative Expenses.

Other general and administrative expenses decreased $0.3 million, or 2%, to $20.0 million for the six months ended June 30, 2020 from $20.3 million for the six months ended June 30, 2019.

Other general and administrative expenses as a percentage of revenues were 16% of revenues for both the six months ended June 30, 2020 and 2019.

Other general and administrative expenses for Workforce Solutions increased $0.9 million to $7.8 million and approximated 8% and 6% of revenues for Workforce Solutions for the six months ended June 30, 2020 and 2019, respectively.

The increase is primarily due to increases in infrastructure expenses and the acquisition of NurseGrid in March 2020 .

Other general and administrative expenses for Provider Solutions decreased $0.1 million to $1.6 million and approximated 7% and 8% of revenues for Provider Solutions for the six months ended June 30, 2020 and 2019, respectively.

Other general and administrative expenses decreased $0.3 million, or 1%, to $29.9 million for the nine months ended September 30, 2020 from $30.3 million for the nine months ended September 30, 2019.

Other general and administrative expenses as a percentage of revenues were 16% of revenues for both the nine months ended September 30, 2020 and 2019.

Other general and administrative expenses for Workforce Solutions increased $1.0 million to $11.3 million and approximated 8% and 6% of revenues for Workforce Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The increase is primarily due to increases in infrastructure expenses and the acquisition of NurseGrid .

Other general and administrative expenses for Provider Solutions decreased $0.2 million to $2.4 million and approximated 7% and 8% of revenues for Provider Solutions for the nine months ended September 30, 2020 and 2019, respectively.

The decrease is primarily associated with lower professional services expenses compared to the prior year period.

The unallocated corporate portion of other general and administrative expenses decreased $1.1 million to $10.6 million compared to the first six months of 2019 primarily due to lower stock based compensation resulting from the impact of the stock awards granted during the three months ended June 30, 2019 as noted above, and decreases in contract labor over the prior year period.

The unallocated corporate portion of other general and administrative expenses decreased $1.1 million to $16.2 million compared to the first nine months of 2019 primarily due to decreases in contract labor over the prior year period and lower stock based compensation resulting from the impact of the stock awards granted the Company’s chief executive officer to employees during the three months ended June 30, 2019, but was partially offset by increased due diligence costs.

Depreciation and Amortization.

Depreciation and amortization increased $1.1 million, or 8 %, to $14.6 million for the six months ended June 30, 2020 from $13.5 million for the six months ended June 30, 2019 .

The increase resulted from an increase in amortization of capitalized software and intangible assets as well as additional depreciation of property and equipment.

Depreciation and amortization increased $1.4 million, or 7%, to $22.0 million for the nine months ended September 30, 2020 from $20.6 million for the nine months ended September 30, 2019.

The increase resulted from an increase in amortization of capitalized software and intangible assets.

Other Income, Net .

Other income, net was $1.9 million for the six months ended June 30, 2020 compared to $1.7 million for the six months ended June 30, 2019.

This increase is a related to the $1.2 million gain associated with the change in fair value of the non-marketable equity investment in NurseGrid prior to the acquisition of NurseGrid on March 9, 2020, offset by lower interest income due to reductions in bond yields and bank interest rates.

Other income, net was $2.0 million for the nine months ended September 30, 2020 compared to $2.5 million for the nine months ended September 30, 2019.

This decrease is related to the $1.2 million gain associated with the change in fair value of the non-marketable equity investment in NurseGrid prior to the acquisition of NurseGrid on March 9, 2020, offset by lower interest income due to reductions in bond yields and bank deposit interest rates.

Income Tax Provision.

The Company recorded a provision for income taxes of $2.9 million and $2.1 million for the six months ended June 30, 2020 and 2019, respectively.

The Company’s effective tax rate was 22% for the six months ended June 30, 2020 compared to 23% for the six months ended June 30, 2019.

The Company recorded additional income tax expense associated with tax deficiencies of $26,000 during the six months ended June 30, 2020 and recorded a reduction to income tax expense for excess tax benefits of $123,000 during the six months ended June 30, 2019.

The Company recorded a provision for income taxes of $3.5 million and $3.3 million for the nine months ended September 30, 2020 and 2019, respectively.

The Company’s effective tax rate was 21% for the nine months ended September 30, 2020 compared to 24% for the nine months ended September 30, 2019.

The Company recorded additional income tax expense associated with tax deficiencies of $30,000 during the nine months ended September 30, 2020 and recorded a reduction to income tax expense for excess tax benefits of $0.1 million during the nine months ended September 30, 2019.

Income from Continuing Operations.

Income from continuing operations was $10.5 million for the six months ended June 30, 2020, up 46% compared to $7.2 million for the six months ended June 30, 2019.

Earnings per diluted share from continuing operations were $0.33 and $0.22 per share for the six months ended June 30, 2020 and 2019, respectively.

Income from continuing operations was $13.2 million for the nine months ended September 30, 2020, up 24% from $10.6 million for the nine months ended September 30, 2019.

Earnings per diluted share from continuing operations were $0.41 and $0.33 for the nine months ended September 30, 2020 and 2019, respectively.

Income from Discontinued Operations.

Income from discontinued operations was zero for the six months ended June 30, 2020 compared to $1.2 million for the six months ended June 30, 2019.

The $1.2 million gain, net of tax, recorded during the six months ended June 30, 2019 was the result of a release of escrow funds to us in connection with the PX disposition.

Income from discontinued operations was zero for the nine months ended September 30, 2020 compared to $1.4 million for the nine months ended September 30, 2019.

The $1.4 million gain, net of tax, recorded during the nine months ended September 30, 2019 was the result of a release of escrow funds to us in connection with the PX disposition.

Refer to Note 10 in the Notes to the Condensed Consolidated Financial Statements for further information.

Net income was $10.5 million for the six months ended June 30, 2020 compared to $8.4 million for the six months ended June 30, 2019.

Earnings per diluted share were $0.33 and $0.26 per share for the six months ended June 30, 2020 and 2019, respectively.

Adjusted EBITDA from continuing operations increased 2% to $23.8 million for the six months ended June 30, 2020 compared to $24.2 million for the six months ended June 30, 2019.

Adjusted EBITDA (from continuing and discontinued operations) decreased $2.1 million to $23.8 million for the six months ended June 30, 2020 compared to $25.9 million for the six months ended June 30, 2019.

Net income was $13.2 million for the nine months ended September 30, 2020 compared to $12.1 million for the nine months ended September 30, 2019.

Earnings per diluted share were $0.41 and $0.37 for the nine months ended September 30, 2020 and 2019, respectively.

Adjusted EBITDA from continuing operations decreased 2% to $34.9 million for the nine months ended September 30, 2020 compared to $35.7 million for the nine months ended September 30, 2019.

Adjusted EBITDA (from continuing and discontinued operations) decreased $2.8 million to $34.9 million for the nine months ended September 30, 2020 compared to $37.7 million for the nine months ended September 30, 2019.

This decrease resulted from the factors mentioned above.

4 unchanged sentences

We recorded a gain on sale, net of tax, of $20.5 million, of which $19.0 million was recorded during the year ended December 31, 2018 and $1.5 million was recorded during the year ended December 31, 2019.

With the proceeds of this sale, our Board of Directors declared a $1.00 per common share special cash dividend, which was paid on April 3, 2018 to shareholders of record on March 6, 2018.

With the proceeds

of this sale, our Board of Directors declared a $1.00 per common share special cash dividend, which was paid on April 3, 2018 to shareholders of record on March 6, 2018.

We have classified the gain on sale of our PX business segment as discontinued operations in our Condensed Consolidated Statements of Income for all applicable periods.

4 unchanged sentences

Revenue generated by HeartCode and RQI products pursuant to the Legacy Agreements was $58.9 million and $54.6 million in 2019 and 2018, respectively.

During the six months ended June 30, 2020, as noted above, we recorded revenue of $21.9 million related to HeartCode and RQI products under the Legacy Agreements compared to $32.8 million for the six months ended June 30, 2019.

During the three months ended June 30, 2020, we recorded revenue of $10.7 million related to HeartCode and RQI products under the Legacy Agreements compared to $15.5 million for the three months ended June 30, 2019.

For the remainder of 2020, we expect quarterly revenue from these products generated pursuant to the Legacy Agreements to continue to decline sequentially each quarter, approximating $8.5 million in the third quarter and $6.0 million in the fourth quarter.

We also continue to expect revenue from HeartCode and RQI products sold pursuant to the Legacy Agreements to be zero in the first quarter of 2021.

During the nine months ended September 30, 2020, as noted above, we recorded revenue of $31.6 million related to HeartCode and RQI products under the Legacy Agreements compared to $46.3 million for the nine months ended September 30, 2019.

During the three months ended September 30, 2020, we recorded revenue of $9.7 million related to HeartCode and RQI products under the Legacy Agreements compared to $13.4 million for the three months ended September 30, 2019.

We expect revenue from these products generated pursuant to the Legacy Agreements to approximate $6.0 million in the fourth quarter of 2020 and to be zero in the first quarter of 2021.

On December 6, 2018, we announced a new agreement with RQI Partners, a joint venture between Laerdal and the American Heart Association.

3 unchanged sentences

RQI Partners will remit a fee to us when new sales of HeartCode and RQI are delivered via the HealthStream Learning Center.

This fee will not be sufficient to supplant the revenue runout associated with the Legacy Agreements, and no material revenues have been recognized under this agreement through June 30, 2020 .

This fee will not be sufficient to supplant the revenue runout associated with the Legacy Agreements, and no material revenues have been recognized under this agreement through September 30, 2020.

We remain actively engaged in efforts to broaden the scope and utilization of our simulation-related offerings to include a range of clinical competencies that extend beyond resuscitation, and we intend to bring to market a broadened scope of simulation-based offerings, including resuscitation programs.

10 unchanged sentences

Adjusted EBITDA and adjusted EBITDA from continuing operations are non-GAAP financial measures and should not be considered as measures of financial performance under GAAP.

Because adjusted EBITDA and adjusted EBITDA from continuing operations are not measurements determined in accordance with GAAP, such non-GAAP financial measures are susceptible to varying calculations.

Because adjusted EBITDA and adjusted EBITDA from continuing operations are not measurements determined in accordance with GAAP, such non-GAAP

financial measures are susceptible to varying calculations.

Accordingly, adjusted EBITDA and adjusted EBITDA from continuing operations, as presented, may not be comparable to other similarly titled measures of other companies.

2 unchanged sentences

Three Months Ended

Six Months Ended

September 30,

Nine Months Ended

September 30,

GAAP income from continuing operations

17 unchanged sentences

Liquidity and Capital Resources

Net cash provided by operating activities decreased by $23.1 million to $13.5 million during the six months ended June 30, 2020 from $36.6 million during the six months ended June 30, 2019.

Such decrease was primarily driven by a decline in legacy resuscitation sales and the impact of COVID-19.

Our DSO was 47 days for the second quarter of 2020, 44 days for the first quarter of 2020, and 47 days for the second quarter of 2019.

Net cash provided by operating activities decreased by $21.8 million to $30.8 million during the nine months ended September 30, 2020 from $52.5 million during the nine months ended September 30, 2019.

Such decrease was largely driven by a decline in cash receipts primarily resulting from the decline in legacy resuscitation sales noted above and lower new sales relative to the prior year period.

Our DSO was 43 days for the third quarter of 2020, compared to 47 days for the second quarter of 2020 and 40 days for the third quarter of 2019.

The Company calculates DSO by dividing the average accounts receivable balance for the quarter by average daily revenues for the quarter.

We believe that developments related to the COVID-19 pandemic have contributed to higher DSO in the second quarter of 2020 compared to the first quarter, the reduction in cash receipts, and lower bookings of new contracts in the first six months of 2020 compared to the same period in 2019, and this trend may continue if negative economic conditions arising from the pandemic persist or continue to deteriorate.

We believe that developments related to the COVID-19 pandemic have contributed to higher DSO during 2020 compared to the prior year, the reduction in cash receipts, and lower bookings of new contracts and renewal of existing contracts in the first nine months of 2020 compared to the same period in 2019, and this trend may continue if negative economic conditions arising from the pandemic persist or continue to deteriorate.

The Company’s primary sources of cash were receipts generated from the sales of our products and services.

The primary uses of cash to fund operations included personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, and general corporate expenses.

Net cash used in investing activities was $22.1 million for the six months ended June 30, 2020 compared to $49.2 million for the six months ended June 30, 2019.

During the six months ended June 30, 2020, the Company spent $21.4 million on business combinations, including the acquisition of NurseGrid and the impact of the working capital adjustment for CredentialMyDoc, invested in marketable securities of $36.9 million, made payments for capitalized software development of $7.6 million, purchased property and equipment of $1.3 million, and invested $1.0 million in non-marketable equity investments .

Net cash used in investing activities was $38.5 million for the nine months ended September 30, 2020 compared to $52.0 million for the nine months ended September 30, 2019.

During the nine months ended September 30, 2020, the Company spent $21.4 million on business combinations, primarily the acquisition of NurseGrid, invested in marketable securities of $61.2 million, made payments for capitalized software development of $12.4 million, purchased property and equipment of $1.7 million, and invested $1.3 million in non-marketable equity investments .

These uses of cash were partially offset by $59.5 million in maturities of marketable securities.

During the six months ended June 30, 2019, the Company acquired Providigm for $18.0 million, invested in marketable securities of $44.2 million, purchased property and equipment of $19.6 million, made payments for capitalized software development of $8.4 million, and invested $3.3 million in non-marketable equity investments.

During the nine months ended September 30, 2019, the Company acquired Providigm for $18.0 million, invested in marketable securities of $58.6 million, purchased property and equipment of $21.5 million, made payments for capitalized software development of $11.2 million, and invested $3.3 million in non-marketable equity investments.

These uses of cash were partially offset by $58.6 million in maturities of marketable securities and $6.0 million in proceeds from the sale of its PX business segment.

Net cash used in financing activities from continuing operations was $10.4 million for the six months ended June 30, 2020 compared to $0.9 million for the six months ended June 30, 2019.

The uses of cash for the six months ended June 30, 2020 primarily included $10.0 million for common stock repurchases, $0.4 million for the payment of employee payroll taxes in relation to the vesting of restricted share units, and $31,000 of cash dividend payments.

The uses of cash for the six months ended June 30, 2019 included $1.0 million for the payment of employee payroll taxes in relation to the vesting of restricted share units, $52,000 of cash dividends payments, and $37,000 of earn-out payments related to prior acquisitions.

The source of cash from financing activities for the six months ended June 30, 2019 was $0.2 million from the exercise of stock options.

Our balance sheet reflects positive working capital of $106.2 million at June 30, 2020 compared to $119.4 million at December 31, 2019 .

Net cash used in financing activities from continuing operations was $16.8 million for the nine months ended September 30, 2020 compared to $0.9 million for the nine months ended September 30, 2019.

The uses of cash for the nine months ended September 30, 2020 primarily included $16.4 million for common stock repurchases, $0.4 million for the payment of employee payroll taxes

in relation to the vesting of restricted share units, and $ 40 ,000 of cash dividend payments.

The uses of cash for the nine months ended September 30, 2019 included $1.0 million for the payment of employee payroll taxes in relation to the vesting of restricted share units, $5 3 ,000 of cash dividends payments, and $3 8 ,000 of earn-out payments related to prior acquisitions.

The source of cash from financing activities for the nine months ended September 30, 2019 was $0.2 million from the exercise of stock options.

Our balance sheet reflects positive working capital of $104.1 million at September 30, 2020 compared to $119.4 million at December 31, 2019.

The decrease in working capital is primarily a result of the reduction in cash to fund the acquisition of NurseGrid and share repurchases.

The Company’s primary source of liquidity as of June 30, 2020 was $112.5 million of cash and cash equivalents and $32.0 million of marketable securities.

The Company also has a $50.0 million revolving credit facility, all of which was available for additional borrowing at June 30, 2020 .

The revolving credit facility expires on November 24, 2020, unless earlier renewed or amended.

The Company’s primary source of liquidity as of September 30, 2020 was $107.0 million of cash and cash equivalents and $42.7 million of marketable securities comprised of corporate debt securities and time deposits.

As of September 30, 2020, the Company also had a $50.0 million revolving credit facility, all of which was available for additional borrowing on such date.

On October 28, 2020, the Company entered into an amendment to this revolving credit facility, which increased the capacity under this facility to $65.0 million and extended the maturity date to October 28, 2023.

On March 13, 2020, we announced a share repurchase program authorized by our Board of Directors under which we may purchase up to $30.0 million of our common stock.

Pursuant to this authorization, repurchases have been made, and may continue to be made from time to time, in the open market through privately negotiated transactions or otherwise, including under a Rule 10b5-1 plan, which permits shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws in accordance with specific prearranged terms related to timing, price, and volume (among others), without further direction from the Company.

Under this program, during the first six months of 2020, we repurchased 443,941 shares at an aggregate fair value of $10.0 million, reflecting an average price per share of $22.53 (excluding the cost of broker commissions).

Under this program, during the first nine months of 2020, we repurchased 762,843 shares at an aggregate fair value of $16.3 million, reflecting an average price per share of $21.42 (excluding the cost of broker commissions).

We may continue to make repurchases under this share repurchase program based on prevailing market conditions, liquidity, and cash flow considerations, applicable securities laws requirements (including under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as applicable), and other factors.

The share repurchase program will terminate on the earlier of March 12, 2021 or when the maximum dollar amount has been expended.

We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development, any additional repurchases under our share repurchase program, and capital expenditures for at least the next 12 months.

We believe that our existing cash and cash equivalents, marketable securities (including time deposits and corporate bond securities), cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development, any additional repurchases under our share repurchase program, and capital expenditures for at least the next 12 months.

If the impact of COVID-19 persists longer than expected or causes economic conditions to further deteriorate, we are prepared to curtail or discontinue new product development and/or repurchases under the share repurchase authorization as we deem in the best interest of shareholders and the Company.

4 unchanged sentences

Therefore, the maximum borrowings against our revolving credit facility would be dependent on the covenant calculations at the time of borrowing.

As of June 30, 2020 , we were in compliance with all covenants.

There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot assure you that if we need additional financing that it will be available on terms favorable to us, or at all.

As of September 30, 2020 , we were in compliance with all covenants.

There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot assure that if we need additional financing that it will be available on terms favorable to us, or at all.

Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition, and results of operations.

Moreover, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruptions of financial and capital markets, which could impair our ability to access additional capital if needed.

Moreover, the COVID-19 pandemic has resulted in, and may continue to result in, disruptions of financial and capital markets, which could impair our ability to access additional capital if needed.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis